Financials

  • Market Capitalization 271.99 M
  • Employee 35
  • Founded 2008
  • CEO N/A
  • Website www.inhibikase.com
  • Headquarter Delaware, United States
  • FIGI BBG005TP2339
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-3.82
Relación precio/flujo de caja
43.33

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
3391
TTRX
Turn Therapeutics Inc. - Common Stock
9.60 USD-0.41%-14.44%+47.24%-4.00%285.97 M USD
3403
GLSI
Greenwich LifeSciences, Inc. - Common stock
19.30 USD+1.53%+6.51%-16.23%+90.52%283.29 M USD
3422
NAGE
Niagen Bioscience, Inc. - Common Stock
3.48 USD+5.78%+2.05%-1.14%-30.12%277.16 M USD
3423
SABS
SAB Biotherapeutics, Inc. - Common Stock
3.66 USD+1.67%-2.92%-6.15%+30.71%279.86 M USD

Noticias